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Introduction
Hypertension is a major cause of cardiovascular 
mortality and morbidity worldwide. In past decades, we
have witnessed the dramatic effects of blood pressure
(BP) lowering in the reduction of mortality and mor-
bidity in patients with diabetes, stroke, heart failure,
and myocardial infarction.1 Unfortunately, BP in the
majority of diagnosed hypertensive patients is still
inadequately controlled.2,3
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Background: Combined regimen may be superior to monotherapy in blood pressure (BP) control. Since BP control is crit-
ically related to cardiovascular mortality and morbidity in hypertensive patients, this study aimed to evaluate the efficacy
and safety of a low-dose combined regimen of preterax compared with cilazapril monotherapy for better BP control in
treated hypertensive patients.
Methods: Stable hypertensive patients were evaluated if their systolic BP (SBP) was > 130 mmHg and/or diastolic BP
(DBP) was > 85 mmHg even with up to 2 antihypertensive drugs. Patients were excluded if they were on angiotensin-
converting enzyme inhibitors, angiotensin II receptor blockers or a diuretic. They were then randomized to receive either
preterax (perindopril 2 mg and indapamide 0.625 mg) or cilazapril 2.5 mg once daily in a double-blind fashion for a period
of 12 weeks after a 2-week placebo run-in phase. Sitting BP was recorded and the safety and efficacy were evaluated at
each visit every 4 weeks. Response was defined as positive if SBP was ≤ 140 mmHg and DBP was ≤ 90 mmHg at the
last visit or there was > 20 mmHg reduction in SBP and/or > 10 mmHg reduction in DBP using either treatment. Plasma
biochemical analysis was performed both before and after the treatment.
Results: Among the 47 patients initially enrolled, 41 completed the study (21 in the preterax group, 20 in the cilazapril
group). There was no difference in the number of adverse events between the 2 groups. SBP was significantly reduced by
preterax (13.43 ± 12.48 mmHg, p < 0.0001) and cilazapril (9.00 ± 13.75 mmHg, p < 0.05). However, DBP was significantly
reduced only by preterax (7.67 ± 9.40 mmHg, p = 0.0009) but not by cilazapril (3.60 ± 8.37 mmHg, p > 0.05). The response
rate was significantly higher to preterax (100%) than to cilazapril (70%) (p = 0.0086).
Conclusion: Though similar in safety, combined regimen preterax was more effective than cilazapril to facilitate adequate
BP control in already-treated hypertensives. It can be added on to other antihypertensives for better BP control in clinical
hypertension. [J Chin Med Assoc 2008;71(5):247–253]
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A number of studies indicated that most patients
required more than 2 kinds of antihypertensive agents
to reach their target BP.4,5 Therefore, a fixed very-
low-dose combination of 2 antihypertensive drugs
has become a popular approach in the initiation of
hypertension treatment. Each drug in the combina-
tion therapy is given at an infra-therapeutic level but
can act synergistically to offer the advantages of in-
creased efficacy and fewer adverse effects.6 The reduc-
tion in the number of tablets required also improves
patient compliance with their antihypertensive treat-
ment. To control BP with a minimal number of drug
tablets may be particularly important when patients’
BP cannot be adequately controlled with current
antihypertensives.
The thiazide diuretics, recommended as first-line
antihypertensive therapy in the Seventh Report of the
Joint National Committee (JNC-VII), have meta-
bolic side effects that can be abolished by combining
them with angiotensin-converting enzyme inhibitors
(ACEIs). Indapamide, a newly designed thiazide-like
diuretic, may minimize the traditional adverse effects
of diuretics on lipoprotein or glucose metabolism and
reduces left ventricular mass in patients with left ven-
tricular hypertrophy. Therefore, preterax, a combina-
tion of perindopril 2 mg and indapamide 0.625 mg,
has been suggested as a better antihypertensive regi-
men. In fact, it was demonstrated in the PREMIER
study that preterax could provide significantly better
BP control and less albumin excretion than enalapril
monotherapy.7 However, it is not known whether its
benefit continues beyond that of other current anti-
hypertensive treatment that the patient may be on.
This study was therefore conducted to evaluate the
add-on efficacy and safety of preterax in patients with
poor BP control by other antihypertensive treatment.
Methods
Study population
This was a randomized, double-blind, parallel-control
study conducted in the hypertensive outpatient clinics
of a single medical center between October 2005 and
January 2007. Eligible patients were those aged from
25 to 75 years old who were on 1 or 2 antihyperten-
sive agents, whatever the pharmacologic class, exclud-
ing ACEIs, angiotensin II receptor blockers and/or a
diuretic, for at least 8 weeks before the outpatient
visit. Seated SBP and DBP were the means of 3 mea-
surements at 2-minute intervals taken with an elec-
tronic sphygmomanometer. Subjects with body mass
index < 30 kg/m2 and BP within the ranges of 130
< SBP < 170 mmHg and/or 80 < DBP < 105 mmHg
were enrolled.
Exclusion criteria were: allergy to perindopril or
indapamide or cilazapril; pregnancy; breast feeding;
secondary hypertension; complicated hypertension
with target organ damage; participation in a drug trial
within the last 1 month; history of unstable angina,
percutaneous coronary angioplasty, coronary bypass
surgery or arterial surgery within the last 3 months;
deep vein thrombosis or pulmonary embolism within
the last 6 months; acute infection; cancer; AIDS; 
alcoholism; drug abuse; heart rate < 50 bpm; pace-
maker; hemoglobin < 10 g/dL; creatinine > 2 mg/dL;
electrolyte imbalance (serum sodium level < 110 or 
> 180 mmol/L or serum potassium level < 3.5 or
> 5.5 mmol/L).
Study design
The study protocol was reviewed by the institutional
committee. After giving written informed consent,
potential eligible individuals commenced a run-in
period with 1 capsule of placebo orally per day and
underwent detailed history-taking, demographic data
measurement, physical examination, chest roentgen-
ography, electrocardiography, and a series of biologic
tests including electrolytes, renal function, liver func-
tion, lipid profiles, uric acid, fasting glucose and blood
cell counts. After 2 weeks, the patients, who were
confirmed to be enrolled, were randomly allocated to
2 active treatment groups: a double-blind comparison
of preterax (perindopril 2 mg + indapamide 0.625 mg)
and cilazapril 2.5 mg once daily for 12 weeks. Each
individual had to maintain his/her original antihy-
pertensive regimen, what he/she took before enrol-
ment without additional antihypertensive agents except
the study treatment, during the whole course of the
study.
Participants were scheduled to visit the physicians
in the outpatient clinics every 4 weeks until the end of
the study. Three measurements of SBP and DBP of
the same arm were taken using an electronic sphyg-
momanometer and with subjects in a sitting position;
the mean of the 3 readings was calculated at all visits,
prior to drug intake. All participants were instructed
to refrain from smoking or ingesting caffeine during
the 30 minutes preceding the measurements. Once
SBP was noted to be <105mmHg or DBP <65mmHg
at any visit, the investigator would be alerted to con-
sider if withdrawal of the subject from the study was
necessary.
Treatment was prematurely and definitively dis-
continued for a participant for any of the following
reasons: pregnancy; personal wish; adverse event 
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requiring study treatment cessation; detection of 
sodium level < 110 mmol/L; loss to follow-up; 
severe hypertension with SBP > 190 mmHg and/or
DBP > 110 mmHg.
Efficacy evaluation
Responders were defined as individuals in whom SBP
was ≤ 140 mmHg and DBP was ≤ 90 mmHg at the
last visit, or whose BP had dropped by > 20 mmHg in
SBP or 10 mmHg in DBP when comparing the selec-
tion visit with the final visit. The primary efficacy end-
point was the response rate in each group. The
secondary endpoints were the range of reductions in
SBP and DBP.
Safety evaluation
All patients were evaluated for safety and compliance
at every visit. The frequencies of adverse effects and
mean variation in heart rate were evaluated. Electrocar-
diography was repeated at the final visit in an attempt
to discover if there were any newly developed abnor-
malities. Another series of biologic tests was also per-
formed at the last visit to check for the presence of
any clinically significant laboratory abnormalities.
Statistical analysis
The analysis was performed in terms of variation
between baseline and the final visit with Wilcoxon
signed rank test. Variation between baseline values and
the final recorded values of BP measured was adjusted
for baseline demographic data. Because the sample
size in each group was less than 30 and the variables
of BP were not normally distributed, the difference in
BP between groups was analyzed using Wilcoxon
rank sum test. After adjusting for the baseline charac-
teristics, response rates were compared by using logis-
tic regression; 95% confidence intervals associated
with between-group differences are given. Statistical
significance was set at p < 0.05.
Results
A total of 56 potentially eligible patients entered the
open-label run-in phase, and 47 (27 men, 57.4%) of
them were subsequently randomized. Twenty-three
patients were treated with preterax, and 24 were
treated with cilazapril. There were 2 patients in the
preterax group (8.7%) and 4 in the cilazapril group
(16.67%) who withdrew from the study due to ad-
verse effects. The main reasons cited for withdrawal
were malaise (1 in the preterax group), cough (1 in
the preterax group and 2 in the cilazapril group),
headache (1 in the cilazapril group) and dizziness (1
in the cilazapril group). The baseline characteristics of
each group are shown in Table 1. In brief, there were
no significant differences between groups in age, body
mass index, SBP and DBP, but there were more men
in the preterax group than in the cilazapril group.
BP reduction
The serial changes in SBP and DBP at each visit are illus-
trated in Figure 1. Only preterax, but not cilazapril,
could lower both SBP and DBP consistently at each
visit.
There were 21 patients in the preterax group and
20 in the cilazapril group who completed the study.
Baseline SBP was 137.73 ± 13 mmHg in the preterax
group and 139.8±12.27mmHg in the cilazapril group.
Baseline DBP was 86.9 ± 8.06 mmHg in the preterax
group and 86.95±5.67mmHg in the cilazapril group.
The change in SBP in the cilazapril group ranged
from +14 to −36 mmHg (mean, −9 mmHg) and from
+ 11 to −37 mmHg (mean, −13.47 mmHg) in the
preterax group. Significant reductions in SBP at the
end of the study were demonstrated in both groups
(p < 0.0001 in the preterax group and p = 0.0109 in
the cilazapril group).
The change in DBP in the cilazapril group ranged
from + 16 to −23 mmHg (mean, −3.6 mmHg) and
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Table 1. Baseline patient characteristics*
Preterax (n = 23) Cilazapril (n = 24) p
Age (yr) 50.26 ± 14.85 56.38 ± 11.92 0.1895†
Sex 0.0254‡
Male 17 (73.91) 10 (41.67)
Female 6 (26.09) 14 (58.33)
Body mass index (kg/m2) 27.02 ± 3.70 26.20 ± 3.95 0.2785†
Blood pressure (mmHg)
Systolic 137.48 ± 12.61 140.21 ± 12.27 0.3536†
Diastolic 86.61 ± 7.92 87.25 ± 6.07 0.8156†
*Data presented as mean ± standard deviation or n (%); †Wilcoxon rank sum test; ‡χ2 test.
from + 4 to −30 mmHg (mean, −7.67 mmHg) in the
preterax group. There was a significant reduction in
DBP in the preterax group (p = 0.0009) but not in
the cilazapril group (p = 0.0594) (Table 2). Between
the 2 groups, there was no significant difference in
BP at baseline or at the final visit, and none in the
range of reduction of BP (Table 2).
Response rate
For the entire enrolled population (n = 47), the
response rates were 95.65% in the preterax group and
66.67% in the cilazapril group (p = 0.0226). After ad-
justing for sex, the response rate was still higher in the
preterax group than in the cilazapril group (p = 0.037).
For the subjects who completed the study (n = 41),
the response rates were 100% in the preterax group
(n = 21) and 70% in the cilazapril group (n = 20;
p = 0.0086). However, the sex was not different
between the 2 groups in this setting.
Safety and adverse events
All adverse events were recognized, including dizzi-
ness (nervous system), cough, respiratory distress
(respiratory system), pain, malaise (body as a whole),
and hematuria (urogenital system). Eleven patients
(47.83%) treated with preterax and 17 (70.83%) with
cilazapril encountered adverse events. There was no
statistically significant difference in the incidence of
adverse events between the 2 groups. The details of
adverse events are shown in Table 3. There were no
serious adverse events and no clinically significant
findings detected on electrocardiography in the over-
all population. There were no significant differences
in biochemistry data between the 2 groups except for
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Figure 1. Mean systolic blood pressure (SBP) and diastolic blood pressure (DBP) at each visit.
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Table 2. Changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline (visit W0) to the last visit (visit W12)*
Preterax (n = 21) Cilazapril (n = 20) p†
SBP (mmHg)
Baseline 137.71 ± 13.00 139.80 ± 12.27 0.4613
W12 124.29 ± 9.14 130.80 ± 14.55 0.1481
Change −13.43 ± 12.48 −9.00 ± 13.75 0.2413
p‡ < 0.0001 0.0109
Difference in mean reduction (95% CI) 4.43 (−3.86, 12.72)
DBP (mmHg)
Baseline 86.90 ± 8.06 86.95 ± 5.67 0.9586
W12 79.24 ± 7.92 83.35 ± 8.42 0.2517
Change −7.67 ± 9.40 −3.60 ± 8.37 0.2413
p‡ 0.0009 0.0594
Difference in mean reduction (95% CI) 4.07 (−1.57, 9.70)
*Data presented as mean ± standard deviation; †Wilcoxon rank sum test; ‡Wilcoxon signed rank test. CI = confidence interval.
a lower plasma potassium level and a higher uric 
acid level in the preterax group compared with the
cilazapril group (p = 0.007 and 0.036, respectively)
(Table 4).
Discussion
The major findings of the present study indicated that
a fixed low-dose combination of perindopril 2 mg and
indapamide 0.625 mg (preterax) could be effective and
safe as a therapeutic add-on strategy to achieve better
BP control in hypertensive patients who are already
being treated. Further, preterax was shown to effec-
tively lower BP, particularly DBP. Compared with
cilazapril, an ACEI, preterax resulted in a significantly
increased response rate in BP reduction in patients
with mild to moderate hypertension whose BP was
not well controlled by their current medications.
Pharmacology and pathophysiology of
combination therapy
Diuretics, particularly thiazides, exert a gradual and
stable hypotensive effect, especially in the elderly and
in patients with poor renal function. They facilitate
the excretion of serum sodium accompanied with a
reduction in body fluid volume and blood pressure.8
However, the causes of hypertension are multifacto-
rial, including sympathetic activity, renin–angiotensin
activation, fluid accumulation and hereditary genes.
Once you block 1 mechanism, others might be com-
pensatorily activated. Accordingly, as BP goes down,
the glomerular capillary pressure drops and glomerular
filtration rate decreases.9 Thereafter follows activation
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Table 3. Adverse events*
Preterax (n = 23) Cilazapril (n = 24) p
Number of patients with adverse events 11 (47.83) 17 (70.83) 0.1081†
Body as a whole 4 (17.39) 3 (12.50) 0.6378‡
Cardiovascular system 4 (17.39) 3 (12.50) 0.6378‡
Digestive system 0 (0) 3 (12.50) 0.2340‡
Metabolic and nutritional disorders 0 (0) 1 (4.17) 1.0000‡
Nervous system 4 (17.39) 6 (25.00) 0.7238‡
Respiratory system 4 (17.39) 7 (29.17) 0.3405†
Skin and appendages 0 (0) 1 (4.17) 1.0000‡
Urogenital system 1 (4.35) 1 (4.17) 1.0000‡
*Data presented as n (%); †χ2 test; ‡Fisher’s exact test.
Table 4. Blood biochemistry tests at baseline and at the final visit*
Preterax Cilazapril
Baseline (n = 23) Final visit (n = 21) Baseline (n = 24) Final visit (n = 20)
Hemoglobin (g/dL) 14.88 ± 1.19 14.50 ± 1.25 14.50 ± 1.16 14.21 ± 1.47†
White cell count (103/µL) 5.67 ± 0.88 6.42 ± 2.05 6.32 ± 1.38 6.10 ± 1.18‡
Platelets (103/µL) 252.52 ± 55.81 260.24 ± 63.00 267.63 ± 73.26 260.05 ± 76.04
Sodium (mmol/L) 141.35 ± 1.43 141.14 ± 1.53 141.42 ± 1.69 140.80 ± 1.67
Potassium (mmol/L) 4.17 ± 0.35 3.89 ± 0.41† 4.24 ± 0.33 4.27 ± 0.32‡
Creatinine (mg/dL) 0.93 ± 0.22 0.95 ± 0.22 0.93 ± 0.25 0.96 ± 0.26
AST (U/L) 23.96 ± 6.22 23.81 ± 4.24 23.13 ± 8.42 24.10 ± 8.92‡
ALT (U/L) 29.00 ± 16.54 27.71 ± 14.38 33.21 ± 17.59 27.30 ± 19.45†
Blood glucose (mg/dL) 98.22 ± 13.76 96.52 ± 9.99 105.29 ± 13.47 104.40 ± 15.86
Total cholesterol (mg/dL) 175.52 ± 24.18 181.43 ± 33.54 223.21 ± 38.69 217.35 ± 29.81
Triglycerides (mg/dL) 112.22 ± 48.09 140.29 ± 105.34 149.96 ± 120.64 125.05 ± 73.61
HDL cholesterol (mg/dL) 38.30 ± 9.11 38.76 ± 7.70 45.17 ± 10.11 44.70 ± 10.03
LDL cholesterol (mg/dL) 122.52 ± 26.35 123.53 ± 36.51 150.71 ± 51.49 157.35 ± 33.69
Uric acid (mg/dL) 6.49 ± 1.21 6.65 ± 1.59 6.49 ± 1.58 6.22 ± 1.38‡
*Data presented as mean ± standard deviation; †Wilcoxon signed rank test was used for within-group analysis, significant difference (p < 0.05) when comparing
the mean values of the baseline and the last visit; ‡Wilcoxon rank sum test was used for between-group analysis, significant difference (p < 0.05) when 
comparing the change between the mean values of the baseline and the last visit in the 2 groups.
of the sympathetic nerve and renin–angiotensin sys-
tem, which are responsible for the vast majority of
diuretic-resistant hypertension cases.10 Therefore, the
concomitant administration of ACEIs will further pro-
mote the natriuretic and hypotensive effects of diuret-
ics. This might be the reason why cilazapril lowered
neither SBP nor DBP consistently at the final visit,
but preterax did. Further, combination therapy with
indapamide and perindopril has been proven to be
effective in reducing arterial stiffness, albuminuria, re-
current stroke, and left ventricular hypertrophy,7,11–16
and it would be reasonable to include it as a first-line
or add-on therapy in clinics.
Response rate to combination therapy
In the Framingham Heart Study, it was found that
even high-normal BP (SBP, 130–139 mmHg; DBP,
85–89 mmHg; or both) augmented the risk of car-
diovascular disease 2-fold compared with lower lev-
els.17 In our study, aggressive treatment using add-on
therapy with preterax resulted in a higher response
rate than to cilazapril, both in the overall study popu-
lation (96.65% vs. 66.67%, p = 0.0226) and in the
subgroup who completed the study (100% vs. 70%,
p = 0.0086). Also, mean DBP was significantly re-
duced in the preterax group rather than in the cilaza-
pril group between the baseline visit and final visit.
Elevated SBP and DBP are common in young hyper-
tensives, compared to isolated systolic hypertension
in the elderly. Preterax, which can lower both SBP
and DBP significantly, might be more suitable for
young hypertensives than cilazapril.
Tolerability of combination therapy
Due to the low dosage of both components of preterax,
good efficacy is accompanied by excellent tolerability
and safety. In previous studies, the safety of combina-
tion therapy with indapamide and perindopril was
comparable or superior to that of other common anti-
hypertensive drugs.7,12,15,18 In our study, we also dem-
onstrated that there was a trend of lower withdrawal
rate in the preterax than in the cilazapril group (8.7%
vs. 16.67%). As drug compliance is a key factor for ef-
ficacious treatment in hypertension as well as for other
diseases, the impact of preterax on patient compliance
and safety needs to be confirmed in future research.
In conclusion, the importance of a fixed very-low-
dose combination therapy has been emphasized as
first-line treatment of hypertension. Though similar
in safety, combined regimen such as preterax, rather
than cilazapril, could be more effective to achieve ad-
equate BP control by being added to already existing
antihypertensive medications. Accordingly, preterax
could be used safely and effectively as an add-on regi-
men for further BP reduction in patients without ade-
quate BP control by other classes of antihypertensive
medications.
Combination therapy has been recommended as
the initial treatment of hypertension in recent trials.
This study demonstrated that combination therapy,
instead of administering a single drug step by step,
constitutes a superior choice for add-on therapy.
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